Company intelligence / Profile preview

Gan & Lee Pharmaceuticals

Beijing, Beijing, Chinaganlee.com ↗

Ownership: Public · 603087.SS
Employees: ~4482
Development stage: Commercial

Overview

Gan & Lee has six core insulin products on the market. Their GLP-1 receptor agonist GZR18 (bofanglutide) demonstrated 16.5 kg weight loss in 35 weeks in Phase Ib/IIa studies and showed efficacy with bi-weekly dosing. Their once-weekly basal insulin GZR4 is in Phase 3 trials in China. The company ranked second overall and first among domestic companies in China's 2024 National Insulin-Specific Centralized Procurement.

Therapeutic areas: Metabolic DisordersOncologyEndocrinologyImmunologyHematologyDermatologyCardiovascular
Modalities: Insulin analogsGLP-1 receptor agonistsNew chemical entitiesBiologics
Industry: Biotech

Drug pipeline

21 assets

GZR4

20 more assets in the full pipeline.

Financials

Market cap: $6.4B
Total revenue: $605.8M
Enterprise value: $5.8B

Beyond the preview

Go deeper on Gan & Lee Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gan & Lee Pharmaceuticals.